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incidence
The incidence of acute myeloblastic leukemia (AML) in adults
in Europe is 5–8 cases/100 000/year. The mortality is 4–6
cases/100 000/year.
diagnosis
The diagnosis of AML requires examination of peripheral blood
and bone marrow samples. Workup should comprise
morphological examination, cytochemistry,
immunophenotyping, cytogenetics and molecular genetics.
risk assessment
Risk assessment in AML includes the patient’s age, the initial
leukocyte count, the AML subtype, karyotype data and selected
molecular markers. AML with the chromosomal translocations
t(15;17) (acute promyelocytic leukemia; APL), t(8;21) and
t(16;16) (including acute myelomonocytic leukemia with
preponderance of eosinophil granulocytes) are considered as
favorable, as are AML with mutations in the C/EBPa gene, and
the nucleophosmin gene [II, A]. An antecedent or concomitant
myelodysplastic syndrome or a complex aberrant karyotype,
alterations of the FLT3 gene are adverse prognostic factors.
Preexisting medical conditions such as diabetes or coronary
heart disease may affect the feasibility of intensive
chemotherapy. Patients beyond the age of 60 years are more
susceptible to treatment complications but also have an adverse
prognosis due to more frequent unfavorable cytogenetics.
If an infection is suspected, a thoracic CT scan, and an
abdominal ultrasound or CT scan may be carried out to assess
lung, liver, spleen, lymph nodes and kidneys for possible
pathological alterations. Cardiac examination including
echocardiography is recommended for patients with cardiac
risk factors or a history of heart disease [A].
In addition to hematological and chemistry tests coagulation
screening is to be carried out before the insertion of central
venous lines and to detect leukemia-related coagulopathy
(particularly if morphology suggests a diagnosis of APL). HLA
typing of patients and their family members is carried out in
patients who are candidates for allogeneic bone marrow or
stem-cell transplantation [A].
treatment plan
Treatment is divided into induction and consolidation
chemotherapy. Whenever possible it should be planned with
a curative intent. Candidates for allogeneic stem-cell
transplantation should be identified early during induction.
Patients with poor performance status and considerable co-
morbidity, as well as elderly patients not eligible for curative
treatment, should receive supportive care. Whenever possible,
AML treatment should be carried out within clinical trials
and in centers offering a multidisciplinary approach. Such
centers should provide an adequate infrastructure, including
a full hematology and medical oncology service, close
collaboration with a bone marrow transplant unit, as well as an
infectious disease expert and adequate transfusion and
psycho-oncology services.
induction chemotherapy
Chemotherapy should be postponed until all material
satisfactory for diagnostic tests has been harvested. Patients
with excessive leukocytosis at presentation may require
emergency leukapheresis before induction chemotherapy.
Induction chemotherapy should include an anthracycline
and cytosine arabinoside [II, A]. Patients failing to respond to
one or two cycles of such treatment are considered refractory.
APL induction chemotherapy should be complemented with
all-trans retinoic acid (ATRA) [II, A]. Hematopoietic growth
factors are an optional adjunct to intensive chemotherapy and
their role in priming leukemic cells during chemotherapy
remains to be confirmed.
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consolidation therapy
Patients entering clinical and hematological remission should
receive one to several cycles of post-remission therapy [II, A].
There is no consensus on a single ‘best’ post-remission
treatment strategy.
Patients with good risk features as defined above should
receive chemotherapy only, preferably with high-dose
cytarabine.
All other patients with an HLA-identical sibling are candidates
for allogeneic stem-cell transplantation in first remission [III, A].
Recently, regimens with dose-reduced conditioning are
increasingly applied, especially in patients >40–45 years. Patients
with particular poor risk features and no donor in the family may
qualify for an allogeneic transplant with an unrelated matched
donor [III, A]. In the situation of a KIR mismatch, haplo-
identical transplants may be considered.
Patients not entering complete remission after induction
therapy are at high risk for failure of treatment and should be
considered candidates for allogeneic transplantation.
The role of high-dose consolidation chemotherapy with
autologous peripheral stem-cell support in AML is
controversial. Maintenance chemotherapy and ATRA are
beneficial in APL only [III, A].
therapy of relapsed or refractory
patients
Patients in second or subsequent remission may qualify for
allogeneic transplantation with an unrelated HLA-matched donor.
In relapsed APL arsenic trioxide can induce remission even if
patients have become refractory to ATRA [III, B].
response evaluation
Response to induction is monitored through clinical
examination, serial peripheral blood counts and bone marrow
aspirates. During induction-induced aplasia a bone marrow
aspirate should be obtained to monitor for early marrow
response or leukemic blast persistence. The usual requirements
of AML remission are a normal cellularity of the bone marrow,
blast levels <5% in bone marrow smears and
morphologically normal hematopoiesis [B].
follow-up
Patients are followed clinically and with hematological
examinations to detect early relapse. Serial bone marrow
examination is of uncertain value in remission patients without
any clinical or hematological evidence of relapse.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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